rs613084 — CPT1A CPT1A carnitine shuttle variant

Intronic variant that influences CPT1A expression and fatty acid oxidation capacity, with effects on HDL cholesterol and desaturase enzyme activity

See your personal result for CPT1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CPT1A — The Rate-Limiting Gateway for Fat Burning

Your liver burns fat by routing long-chain fatty acids into mitochondria — the cellular power plants. But fatty acids can't cross the inner mitochondrial membrane on their own. They need a molecular escort. That escort is the carnitine shuttle11 carnitine shuttle
a two-enzyme system that attaches a carnitine molecule to fatty acids, enabling mitochondrial entry, and the enzyme that initiates it — carnitine palmitoyltransferase 1A (CPT1A) — is the rate-limiting bottleneck for all hepatic fat oxidation.

rs613084 is an intronic variant that acts as a cis-regulatory switch for CPT1A expression in liver tissue. Your genotype here influences how much CPT1A your liver produces, which in turn governs how efficiently you clear long-chain fats, influence circulating triglyceride levels, and generate HDL cholesterol.

The Mechanism

CPT1A sits on the outer mitochondrial membrane and catalyzes the acylcarnitine22 acylcarnitine
the carnitine-linked form of a fatty acid that can traverse the mitochondrial membrane conversion step. Its activity is tightly regulated by malonyl-CoA33 malonyl-CoA
a metabolic intermediate that rises when energy is plentiful, signaling the cell to store rather than burn fat, which binds the enzyme's N-terminal domain and acts as an allosteric brake. When CPT1A expression is higher, more enzyme is available to handle fat-burning demand even under partial malonyl-CoA inhibition; when expression is lower, long-chain fatty acids back up in the cytoplasm and are re-esterified as triglycerides rather than oxidized.

rs613084 lies within CPT1A intron 1 — a genomic region that, based on parallel methylation research in the GOLDN study44 GOLDN study
Genetics of Lipid Lowering Drugs and Diet Network — a large family-based study of European-ancestry adults, appears to be a major regulatory hub for CPT1A transcription. Two CpG sites in this same intron associate with fasting triglycerides at genome-wide significance (p=5.3×10⁻¹⁴) and with VLDL-C, adiponectin, insulin, and HOMA-IR. The A allele at rs613084 has been shown to correlate with higher CPT1A transcript levels in a cis-eQTL analysis of Mexican American families (SAFHS cohort).

The Evidence

The primary genetic evidence for rs613084 comes from the GOCADAN study55 GOCADAN study
Genetics of Coronary Artery Disease in Alaska Natives, n=761 Alaskan Eskimos, where rs613084 emerged as one of three independent CPT1A variants significantly associated with estimated delta-5 desaturase (D5D) activity — the rate-limiting enzyme for ω-3 and ω-6 fatty acid conversion — at p=6.7×10⁻⁵ for HDL-C and reaching p values as low as 1.6×10⁻⁹ for erythrocyte D5D activity. The A allele associated with higher D5D activity and elevated HDL-C. Importantly, the CPT1A expression association was replicated in Mexican Americans66 replicated in Mexican Americans
San Antonio Family Heart Study (SAFHS), a large independent family-based cohort of Mexican-American adults (p=1.14×10⁻⁶²), making this one of the strongest cis-eQTL signals for CPT1A in liver-relevant tissue and confirming the finding across ethnic groups.

The indirect link between CPT1A expression and D5D activity is thought to reflect a shared regulatory network: both enzymes participate in fatty acid flux decisions in the liver, and CPT1A activity influences the availability of fatty acid substrates for FADS-family desaturases. Higher CPT1A expression means more substrate is diverted toward oxidation, which alters the pool available for desaturation and incorporation into phospholipids and lipoproteins — explaining the observed HDL-C effect.

Practical Actions

The A allele at rs613084 is associated with modestly higher CPT1A expression and more efficient hepatic fatty acid oxidation, reflected in higher HDL-C. This variant has no drug interactions and is not pathogenic. Its primary practical relevance is in optimizing dietary fat composition and supporting the carnitine shuttle that CPT1A depends on.

Long-chain fatty acids require L-carnitine as a cofactor for CPT1A-mediated transport. Individuals with lower CPT1A expression (CC genotype) have less enzymatic reserve for fat oxidation and may benefit more from dietary and supplementation strategies that support carnitine availability.

Interactions

rs613084 acts within the same functional network as rs3019594 and rs11228368 — two other independent CPT1A intronic variants identified in the GOCADAN study. Together these three SNPs tag distinct haplotype blocks across the CPT1A intron 1 regulatory region. They may interact additively on expression.

The Arctic-prevalence CPT1A P479L variant (rs80356779) — a missense variant with reduced malonyl-CoA sensitivity and lower catalytic activity — is a distinct functional allele in the same gene with independent population genetics and a separate biological mechanism. Compound effects of rs613084 with rs80356779 have not been formally studied but would be relevant in Arctic-ancestry populations carrying both.

Nutrient Interactions

long-chain fatty acids altered_metabolism
L-carnitine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard Fat Oxidation Normal

Reference genotype — baseline CPT1A expression and fat-burning capacity

The CPT1A intron 1 region containing rs613084 is a regulatory hotspot. The C allele at this position corresponds to baseline CPT1A transcription. CpG methylation studies in the overlapping GOLDN cohort (European ancestry, n=846) confirm this region's central role in triglyceride and VLDL-cholesterol metabolism, though those studies focus on epigenetic variation rather than the genetic variant itself. Your standard CPT1A expression means that malonyl-CoA inhibition operates normally — fat oxidation is appropriately downregulated when carbohydrates are being metabolized, and upregulated during fasting or sustained exercise.

AA Enhanced Fat Oxidation Beneficial

Two A copies — highest CPT1A expression and strongest fat-oxidation capacity

The eQTL signal at this locus is additive: each A allele incrementally raises CPT1A transcription. The GOCADAN study identified rs613084 as one of three independent CPT1A intronic SNPs associated with desaturase activity and HDL-C simultaneously — rs613084 reached p=6.7×10⁻⁵ for HDL-C and p values extending to 1.6×10⁻⁹ for erythrocyte D5D activity across related tests. The CPT1A expression effect was replicated at p=1.14×10⁻⁶² in the SAFHS Mexican American cohort.

From a physiological standpoint, higher CPT1A expression shifts the liver toward oxidative metabolism for long-chain fats: more fatty acid enters the TCA cycle via β-oxidation, less is packaged as VLDL triglycerides, and HDL rises as a secondary consequence of improved triglyceride clearance. This also increases the supply of long-chain fatty acid substrates to FADS-family desaturases (FADS1, FADS2), explaining the elevated D5D activity observed in the same study. The CPT1A methylation research from GOLDN — where hypomethylation of the intron 1 regulatory region associates with lower fasting triglycerides (p=5.3×10⁻¹⁴) — provides independent epigenetic evidence that this regulatory region controls the same metabolic phenotype.

AC Moderately Enhanced Fat Oxidation Intermediate

One A copy — modestly elevated CPT1A expression and improved fat-burning capacity

The cis-eQTL effect of the A allele on CPT1A expression was confirmed at p=1.14×10⁻⁶² in the SAFHS Mexican American cohort — an extremely robust signal for a regulatory variant. With one copy, you likely produce intermediate CPT1A levels compared to homozygotes at either end. The HDL-C association observed in the GOCADAN study (p=6.7×10⁻⁵) is consistent with a dose-dependent effect: greater CPT1A-mediated fatty acid clearance reduces hepatic lipid accumulation, lowering VLDL secretion and secondarily elevating HDL via reduced triglyceride-rich lipoprotein competition.